Live feed08:00:00·553dPRReleasevia QuantisnowPluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host DiseaseByQuantisnow·Wall Street's wire, on your screen.PLUR· Pluri Inc.Health Care
